FY24: Logistics & IT, digital innovation shine bright

12/03/25 -"Galenica reported a strong FY 2024 performance, with sales increasing by 4.7%, driven by growth across all segments except ‘at-home’ pharmacies. Adjusted EBIT increased by 10.3%, ..."

Executive summary
Conflict of interest

Pages

Language

English

Published on

12/03/25

Download

You may also be interested by these reports :

17/03/25

Allegro.eu

Although Allegro generated a 2024 EPS only slightly lower than we had expected (PLN1.06 vs. PLN1.13), we have reduced our estimates for 2025 (PLN1.48 ...

13/03/25

Inditex

Inditex delivered another strong year, exceeding both consensus and our expectations. Revenue growth accelerated towards the year-end compared to the ...

13/03/25

Allegro.eu

Allegro Group’s Q4 24 results were 0.6-25% above the PAP consensus at the sales and adj. EBITDA level, but 2.4%-17% below on EBIT and net income. ...

13/03/25

DocMorris

Potential capital increase. No FY25E guidance. Rx sales of +50% in QTD

EXECUTIVE SUMMARY

Updates

Pension Risks

Target & Opinion

Governance & Management

Business & Trends

Graphics : Momentum

Money Making

Graphics : MACD & Volumes

Debt

Graphics : Sensitivities

Valuation

Sector: Performance

DCF

Sector: Key data

NAV/SOTP

Sector: Ratios & Valorisation

Worth knowing

Sector: Peers

Financials

Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking

Trading in corporate shares

Analyst ownership

Advising of corporate (strategy, marketing, debt, etc)

Research paid for by corporate

Provision of corporate access paid for by corporate

Link between and a banking entity

Brokerage activity at AlphaValue